Thomas Patrick Kelly insider trades: Xenon Pharmaceuticals (XENE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | XENE | ↑ Buy | 15,000 | $37.32 | $560K | Direct | Oct 1, 2026 (1d) |
| Feb 16, 2024 | DCPH | ↓ Sell | 3,010 | $15.62 | $47K | Direct | Feb 20, 2024 (4d) |
| Jan 16, 2024 | DCPH | ↓ Sell | 2,435 | $14.47 | $35K | Direct | Jan 18, 2024 (2d) |
| Dec 13, 2023 | DCPH | ↓ Sell | 2,792 | $15.37 | $43K | Direct | Dec 14, 2023 (1d) |
| Oct 30, 2023 | DCPH | ↓ Sell | 2,316 | $12.02 | $28K | Direct | Oct 31, 2023 (1d) |
| Jun 16, 2023 | DCPH | ↓ Sell | 1,655 | $14.40 | $24K | Direct | Jun 21, 2023 (5d) |
| Feb 16, 2023 | DCPH | ↓ Sell | 1,370 | $15.10 | $21K | Direct | Feb 17, 2023 (1d) |
| Jan 17, 2023 | DCPH | ↓ Sell | 2,403 | $21.24 | $51K | Direct | Jan 19, 2023 (2d) |
| Jun 16, 2022 | DCPH | ↓ Sell | 1,768 | $10.75 | $19K | Direct | Jun 21, 2022 (5d) |
| Feb 16, 2022 | DCPH | ↓ Sell | 1,368 | $9.05 | $12K | Direct | Feb 18, 2022 (2d) |
| Feb 16, 2021 | DCPH | ↓ Sell | 524 | $48.87 | $26K | Direct | Feb 18, 2021 (2d) |
| Sep 14, 2020 | DCPH | ↓ Sell | 3,000 | $50.01 | $150K | Direct | Sep 16, 2020 (2d) |
| Sep 10, 2020 | DCPH | ↓ Sell | 9,000 | $46.23 | $416K | Direct | Sep 10, 2020 (0d) |
| May 11, 2020 | DCPH | ↓ Sell | 12,000 | $55.19 | $662K | Direct | May 13, 2020 (2d) |
| Jan 3, 2020 | DCPH | ↓ Sell | 12,000 | $57.65 | $692K | Direct | Jan 6, 2020 (3d) |
| Dec 23, 2019 | DCPH | ↓ Sell | 40,000 | $68.21 | $2.7M | Direct | Dec 26, 2019 (3d) |
| Oct 28, 2019 | DCPH | ↓ Sell | 3,750 | $40.00 | $150K | Direct | Oct 30, 2019 (2d) |
| Sep 11, 2019 | DCPH | ↓ Sell | 11,250 | $34.97 | $393K | Direct | Sep 13, 2019 (2d) |
| Aug 13, 2019 | DCPH | ↓ Sell | 11,250 | $41.27 | $464K | Direct | Aug 13, 2019 (0d) |
| Jun 19, 2019 | DCPH | ↓ Sell | 177 | $25.00 | $4K | Direct | Jun 21, 2019 (2d) |
| Jun 3, 2019 | DCPH | ↓ Sell | 2,100 | $25.20 | $53K | Direct | Jun 5, 2019 (2d) |
| May 22, 2019 | DCPH | ↓ Sell | 1,473 | $25.06 | $37K | Direct | May 23, 2019 (1d) |
| May 1, 2019 | DCPH | ↓ Sell | 13,500 | $22.93 | $310K | Direct | May 3, 2019 (2d) |
| Feb 19, 2019 | DCPH | ↓ Sell | 1,500 | $30.00 | $45K | Direct | Feb 20, 2019 (1d) |
| Jan 7, 2019 | DCPH | ↓ Sell | 5,000 | $25.18 | $126K | Direct | Jan 9, 2019 (2d) |
| Aug 22, 2007 | CRTX | ↑ Buy | 4,000 | $2.08 | $8K | Direct | Aug 22, 2007 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other XENE insiders
Open-market trades in the last 12 months
About Thomas Patrick Kelly's insider trades
Thomas Patrick Kelly is Chief Financial Officer at Xenon Pharmaceuticals (XENE). Since Aug 22, 2007, Thomas has reported 2 open-market purchases worth $568K and 24 sales worth $6.5M on SEC Form 4. In the last 12 months: 1 buy ($560K).
Their filings also include option exercises (16 filings), grants and awards (15 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XENE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.